title: [Myeloid crisis of chronic myelogenous leukemia showing dramatic response to mithramycin and hydroxyurea combination].
abstract: After 4 years of chronic phase, a 22-year-old female with Ph1 (+) chronic myelogenous leukemia developed myelomonocytic crisis. On admission, her Hb was 9.9 g/dl, Plt 4.1 x 10(4)/microliters, WBC 138,000/microliters with 16.5% blasts. Bone marrow contained 38% blasts. She received a combination chemotherapy of mithramycin and hydroxyurea, as reported by Koller et al. Dose of mithramycin was reduced to 20 micrograms/kg. Following 1st and 2nd infusions of mithramycin, severe nasal bleeding was seen. Prednisolone 10 mg/day was given from the 3rd dose of mithramycin with apparent hemostatic effects. Calcium gluconate 3 g/day was administered concomitantly. Her disease responded promptly to this treatment and hematological remission was achieved.
authors.forename: K
authors.initials: K
authors.lastname: Ueki
authors.forename: A
authors.initials: A
authors.lastname: Tsuchida
authors.forename: H
authors.initials: H
authors.lastname: Murakami
authors.forename: M
authors.initials: M
authors.lastname: Karasawa
authors.forename: N
authors.initials: N
authors.lastname: Kobayashi
authors.forename: M
authors.initials: M
authors.lastname: Omine
authors.forename: T
authors.initials: T
authors.lastname: Naruse
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001752:Blast Crisis; D005260:Female; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000473:pathology; D008926:Plicamycin / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D008926:Plicamycin; D006918:Hydroxyurea